The 'Newly Acquired Information' Shift In Pharma Litigation

Law360 (June 10, 2019, 3:30 PM EDT) -- There has been a sea change in pharmaceutical litigation over the last four years. Before 2015, the key issue on which most pharmaceutical litigation generally turned was the adequacy of the warning given the prescribing physician; litigation was characterized by testimony about the physician’s subjective knowledge of drug-related risks, experience with the drug in question and prescribing habits.

Those issues remain central to the ultimate outcome in these lawsuits (indeed, a failure-to-warn plaintiff cannot meet his or her burden of proof without it). But a survey of pharmaceutical litigation reveals that many of these cases now turn on a more narrow...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS